Reticulocyte Count
Reticulocytes are immature (young) red blood cells from which the nucleus has been extruded but the cells still contain some cytoplasmic RNA and organelles. In normal healthy individuals, reticulocytes account for 0.5% to 1.5% of the circulating peripheral red blood cells. Newborn infants have a higher count; this will usually fall to the adult level around the second week of life. Normally, reticulocytes will lose their RNA approximately a day after entering the bloodstream from the marrow. A reticulocyte count is clinically helpful to determine whether the bone marrow is responding appropriately (erythropoietic activity) to a low hemoglobin event by producing red blood cells to resolve the anemia. The cells are visualized by staining with vital dyes that precipitate the RNA and organelles. This test is indicated in the evaluation of anemia to distinguish hypoproliferative anemia, hemolytic anemia, or blood loss. It is also used to monitor anemic states, aplastic anemia therapy, and to evaluate the cause of overproduction of red blood cells. Interpretation must take into account the age and nutritional status of the patient. Automated instrumentation such as flow cytometry results in much better reproducibility since manual methods have many drawbacks, one of which is sample error where too few RBCs are counted. To help rectify this, a manual count usually consists of at least 1000 RBCs and the reticulocyte count is calculated appropriately.
- Diagnostic in the evaluation of erythropoietic activity
- Evaluation of erythropoietic response to therapy of various anemias
- Aids diagnosis of iron deficiency
- As an aid in diagnosis of myelodysplastic syndrome
Increased in:
- Increased erythropoiesis as in hemolytic anemia
- Erythropoiesis secondary to acute blood loss (with adequate storage iron)
- Recovery from iron, B12 or folate deficiency following treatment
- Drug-induced anemia
Decreased in:
- Iron deficiency anemia
- Aplastic anemia
- Anemia of chronic disease
- Megaloblastic anemia
- Sideroblastic anemia
- Pure red cell aplasia
- Renal disease
- Bone marrow suppression (drugs, toxins or radiation) or infiltration
- Myelodysplastic syndrome
- Transient erythroblastopenia of childhood
| Age | Percent (%) | Fraction |
| Newborn | 3–7 | 0.03–0.07 |
| 1 day | 3–7 | 0.03–0.07 |
| 3 days | 1–3 | 0.01–0.03 |
| 7 days | 0–1 | 0.00–0.01 |
| 1 month | 0.2–2 | 0.002–0.02 |
| 1.5 months | 0.3–3.5 | 0.003–0.035 |
| 2 months | 0.4–4.8 | 0.004–0.048 |
| 2.5 months | 0.3–4.2 | 0.003–0.042 |
| 3 months | 0.3–3.6 | 0.003–0.036 |
| 4–12 months | 0.2–2.8 | 0.002–0.028 |
| Adult | 0.5–1.5 | 0.005–0.015 |
Whole Blood EDTA (Lavender) or Capillary Blood with direct dilution.
Stability
- Ambient: 24 hrs
- Refrigerated: 48 hrs
- Am J Clin Pathol. 2002;117:871. [PMID: 12047138]
- Int J Clin Lab Res. 1998;28(1):1-11. [PMID: 9594357]
- Hematol Oncol Clin North Am. 2002;16:373. [PMID: 12094477]
- Jacobs DS and DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001)
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757